OncoMatch/Clinical Trials/NCT05615974
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
Is NCT05615974 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including LM101 and Toripalimab for malignant tumors.
Treatment: LM101 · Toripalimab · Rituximab — This study is to assess the safety and tolerability, obtain Maximum Tolerated Dose (MTD) and/or the recommended phase 2 dose (RP2D) of LM-101 as a single agent or in combination in patients with advanced malignant tumors
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy
have progressed on standard therapy
Cannot have received: investigational therapy directed at the same target
Subject has received prior investigational therapy directed at the same target therapy
Cannot have received: any anti-tumor treatment
Exception: within 21 days prior to the first dosing of LM-101
Subjects with anti-tumor treatment within 21 days prior to the first dosing of LM-101, including radiotherapy, chemotherapy, endocrine therapy, and immunotherapy, etc.
Cannot have received: participation in other interventional clinical trial
Exception: within 21 days prior to the first dosing of LM-101
Subjects has participated in any other interventional clinical trial within 21 days prior to the first dosing of LM-101
Cannot have received: major surgery or interventional treatment
Exception: within 28 days prior to the first dosing of LM-101 (excluding tumor biopsy, puncture, etc.)
Subjects who received major surgery or interventional treatment within 28 days prior to the first dosing of LM-101 (excluding tumor biopsy, puncture, etc.)
Lab requirements
Blood counts
Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose
Kidney function
Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose
Liver function
Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose
Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05615974 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational therapy directed at the same target, any anti-tumor treatment, participation in other interventional clinical trial disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify